trial
as of 2026-07-01Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
NCTId NCT04709224
at a glance
Phase 1 · Completed
Enrollment 37 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2022-05-23
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2020-12-30
Primary completion
2022-05-23
Eligibility
ALL · 18 Years · 50 Years
Interventions & indications
Indications
Sponsors
Intra-Cellular Therapies, Inc.Lead Sponsor
Sites
2 total
Long Beach, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
37
Phase
PHASE1
Primary Completion Date
2022-05-23
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
indication
indication